Tag: immunotherapy
Search News
New phase III clinical trial using combination therapy extends survival in triple-negative breast cancer
22nd October 2018
Research provides new hope for people with an aggressive type of breast cancer.
Read more
Immunotherapy shows promise for patients with metastatic triple-negative breast cancer
17th October 2018
Immunotherapy has been shown to confer an encouraging survival benefit in patients with metastatic triple-negative breast cancer (mTNBC).
Read more
Blood Cancer Awareness Month 2018
28th September 2018
Blood Cancer Awareness Month takes place every September to raise awareness of the challenges faced by those living with blood cancer. In the UK, blood cancer is the fifth most common cancer, with 240,000 people living with the disease and 38,000 people being diagnosed with a type of blood cancer each year.
Read more
Pancreatic Cancer UK Grand Challenge
27th July 2018
Our Director, Prof Nicholas Lemoine, and a team of researchers from the BCI and King’s College London have been awarded the Pancreatic Cancer UK (PCUK) Grand Challenge- PCUK’s largest ever research fund. The grant will be […]
Read more
London Pancreas Workshop 2018
11th May 2018
On Friday 4th May, BCI hosted the seventh London Pancreas Workshop, co-organised by Prof Hemant Kocher and our Director Prof Nick Lemoine, which attracted delegates from across Europe and America, with over 140 attendees in total. The biennial event is recognised as a forum for state-of-the-art clinical and basic research in pancreatic cancer.
Read more
BCI and KCL collaboration develops a clinically-relevant CAR T cell imaging system
19th April 2018
A collaboration involving researchers from BCI’s Centre for Molecular Oncology, led by Dr Jane Sosabowski, and the ImmunoEngineering Group of King’s College London (KCL), led by Dr Sophie Papa, has developed an effective and clinically-relevant imaging system to monitor chimeric antigen receptor (CAR) T cells within the body. This system reduced the tumour burden in a pre-clinical model of prostate cancer and allowed for repeated and non-invasive assessment of CAR T cell localisation.
Read more